den uijl iem et al. haemophilia 17: 849-853 (2011) · 2018-01-13 · mild and moderate haemophilia...
TRANSCRIPT
Dr. Paul GiangrandeGreen Templeton College
University of Oxford
Mild and moderate haemophilia:introduction
ISTH definitions:White GC et al. Thromb. Haemost. 85: 560 (2001)
Categories defined by factor VIII/IX level:• Severe haemophilia: < 1% (0.01 IU/ml)• Moderate haemophilia: 1-5%• Mild haemophilia: > 5% - < 40%
The term “nonsevere” is increasingly beingused in clinical studies to include both patientswith mild and moderately severe haemophilia
den Uijl IEM et al. Haemophilia 17: 849-853 (2011)
den Uijl IEM et al. Haemophilia 17: 849-853 (2011)
Challenges of nonseverehaemophilia:
• Far more nonsevere than severe patients• Diagnosis often delayed• Patients generally far less engaged with
specialist haemophilia centres• Danger of complacency: risk of bleeding
underestimated by patients and doctors• Not trained to self-infuse concentrates• Some of these patients develop inhibitors
– Dramatic impact on bleeding pattern
Sports-related injuries in mildhaemophilia:
One stage clotting ChromogenicPatient sample
• Factor deficient plasma• aPTT reagent & Ca++
Met
hod
Goa
lM
etric
• Purified proteins• Ca++
• Fibrin formation
• Turbidity
• FXa generation
• Colorimetric
Relevance to diagnosis:• Significant discrepancy between results of
one stage and two stage/chromogenic FVIIIassays in large proportion of patients withmild and moderate haemophiliaPoulsen Al et al. Haemophilia 15: 285-289 (2009)
• One stage result may be normal whilst twostage/chromogenic assay result is low
• Bleeding tendency correlates best withlower two stage/chromogenic result
• No discrepancy in severe haemophilia
Relevance to diagnosis:
• Some reports of reverse discrepancy (low onestage/normal chromogenic) but these patientsgenerally have no bleeding symptoms
• If you only use a one stage assay:– Some cases of mild haemophilia will be missed– Some patients with moderate haemophilia will be
incorrectly labelled as mild– Some normal subjects will be incorrectly labelled
as having a bleeding disorder
Potgieter JJ et al. Eur J Haematology 94 (Suppl. 77): 38-44 (2015)
Type 2N VWD:• Often mistaken for mild haemophilia A• Defect is in N-terminal of VWF: factor VIII
binding to VWF is impaired• Three mutations in exons 18-20 account for ≈
95% of cases: T791M, R816W, R854Q• Factor VIII typically in range 3-15 iu/dl (%)• VWF levels all normal (Ag/RCo/CB)• Bleeding time is normal• Autosomal recessive inheritance: both sexes
affected in family tree• DNA-based studies will confirm diagnosis
• FVIII binding assay an alternative test
Lancet 309: 869-872 (1977)
DDAVP: what is new?• Response improves with age
Revel-Vilk S et al. Br J Haematol 117: 847-951 (2002)
• Response dependent on F8 mutationStoof SCM et al. Thromb Haemostas 109: 440-449 (2013)
– Poor response with R2169H and P149R• Lower absolute increase in factor VIII level
observed in patients with blood group OMauser-Bunschoten EP et al. J Thromb Haemostas 11: 2179-2181 (2013)
• Safe to use during pregnancy in carriersTrigg DE et al. Haemophilia 18: 25-33 (2012)
• May be of therapeutic benefit in somecases of type 2 VWD (not just type 1)
Inhibitor development innonsevere haemophilia:
Eckhardt C and INSIGHT Study Group. Blood 122: 1954-1962 (2013)
• 1112 nonsevere haemophilia A patientsfrom 14 centres in Europe and Australiathat had genotyped ≥ 70% of their patients
• During 44,800 exposure days (median, 24per patient), 59 of the 1112 patientsdeveloped an inhibitor:– Cumulative incidence of 5.3%– After a median of 28 exposure days
Inhibitor development innonsevere haemophilia:
Eckhardt C and INSIGHT Study Group. Blood 122: 1954-1962 (2013)
• The inhibitor risk after 50 exposure dayswas 6.7% (95% CI, 4.5-8.9)
• The risk increased to 13.3% after 100exposure days (95% CI, 9.6-17.0)
• Among a total of 214 different F8missense mutations, 19 were associatedwith inhibitor development
• These results emphasize the importanceof F8 genotyping in nonsevere hemophilia
Outcome and eradication strategies:van Velzen A and INSIGHT Study Group. Thromb Haemostas 114: 46-55 (2015)
• 101 inhibitor patients from a sourcepopulation of 2,709 nonsevere HA patients– Median age 37 years; median peak titre 7 BU/ml
• Inhibitor disappeared in 72/101 (71%)– Spontaneously 51/73 (70%)– After eradication treatment 21/28 (75%)
• Eradication strategies varied widely– Conventional immune tolerance induction and
immunosuppression
Outcome and eradication strategies:van Velzen A and INSIGHT Study Group. Thromb Haemostas 114: 46-55 (2015)
• Anamnestic response seen after rechallengein 25/72 (35%) of patients who lost antibodies– Disappearance does not always equal sustained
response• Sustained success was observed in 64 %
(30/47) of patients rechallenged• In high-titre inhibitor patients, eradication
treatment was associated with sustainedsuccess (RR 2.3)
Principal conclusions:• Need to improve engagement of nonsevere
patients with treatment centres• Patients and health care professionals often
underestimate potential for bleeding– Bleeds caused by sporting injuries can be severe
• Response to DDAVP linked to F8 mutations• Patients can develop inhibitors after treatment
with coagulation factor concentrates• Chromogenic assay best for reliable diagnosis• Always exclude possibility of 2N VWD